An interventional study of Honest Open Proud program in Psychotic Disorders, Bipolar Disorder and Disclosure, sponsored by Oslo University Hospital. Completed at 2 sites in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Psychotic Disorders with a site in Norway — 6 open to participants now, 7 under way, none of them phase 3. Psychotic Disorders · Norway.
Among the 26 studies in Psychotic Disorders with a site in Norway, this one is the 16th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, and was the 23rd registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →6 of the 26 studies in Psychotic Disorders with a site in Norway are open now. Recruiting first, the newest first:
Philipp Homan · Sites in Norway, Czechia, Ireland and 3 more countries
Ages 18–65 · Healthy volunteers
Oslo University Hospital · Sites in Norway
Ages 17–65
Haukeland University Hospital · Sites in Norway
Ages 16+
Vestre Viken Hospital Trust · Sites in Norway
Ages 18+
Sykehuset i Vestfold HF · Sites in Norway
Ages 18–65
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 2 · Phase 4 4
First in 2001; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 87 across the 20 interventional studies, 211 across the 6 observational. Of the 16 that completed or were terminated, 3 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 26 have an industry lead sponsor. The 10 most frequent:
Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.
Oslo University Hospital has 7 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies in Psychotic Disorders with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05719116Solli Distriktspsykiatriske SenterA Combined Aerobic and Resistance Training Program for Adults With Psychotic Disorders | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Psychotic Disorders with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this pilot study is to evaluate the feasibility, acceptability and efficacy of a Norwegian adaptation of the group-based intervention 'Honest Open Proud' among adults with psychotic and bipolar disorders in an outpatient setting.
Because people with mental illness experience both public and personal stigma, which is related to lower levels of recovery and wellbeing, it is common to struggle with decisions regarding potential disclosure of mental health difficulties or diagnoses. There are pros and cons with both disclosure and secrecy. Disclosure can lead to social support, followed by improved mental health and reduced public stigma, but also stigmatization and social exclusion. Secrecy can prevent stigmatization but may also lead to social isolation and thus poorer mental health and increased public stigma. Therefore, people with mental illness need help to make strategic decisions about whether, and if so, to whom, when and how they wish to disclose their mental health problems. As contact with other people with mental health difficulties is crucial to anti-stigma interventions, people with mental illness could benefit from meeting peers, especially as role models. This suggests that peer facilitators could be an important feature in a program aiming to help people with mental illness handle stigma and challenges related to disclosure. The Honest Open Proud (HOP) program was developed for this purpose. Because people with psychotic and bipolar disorders experience particularly high levels of both public and personal stigma, which negatively impacts their recovery rates, they may be especially in need of the HOP program.
The investigators aim to evaluate whether a Norwegian adaptation of the HOP group program, which is facilitated by peers, is feasible and acceptable for people with psychotic and bipolar disorders in an outpatient setting. Moreover, whether it helps them handle stigma and disclosure related decisions.
The investigators propose a pilot randomized controlled trial, comparing an intervention group receiving a 6-week Norwegian adaptation of the HOP program to a waiting list control group. Both groups receive treatment as usual. The main research question is whether this intervention is feasible and acceptable. However, efficacy measures tapping change in stigma and disclosure distress, as well as recovery and wellbeing, from before to after the intervention, were included. The aim is to find what effect sizes can be expected in future larger studies in Norway, rather than to find significant differences in effect sizes. We also added a descriptive follow-up 6-24 months (depending on cohort) after the intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention group: receives the HOP program consisting of four 2-hour sessions divided between week 1, week 2, week 3 and week 6, in groups of 4-10 participants, using a Norwegian adaptation of HOP workbook. The intervention group also receives treatment as usual, consisting of weekly or monthly appointments with a mental health care professional at an outpatient unit in the public mental health care service. The appointments can involve medication management, psychoeducation, support therapy or psychotherapy.
Behavioral: Honest Open Proud program
Waiting list control group: receives only treatment as usual, consisting of weekly or monthly appointments with a mental health care professional at an outpatient unit in the public mental health care service. The appointments can involve medication management, psychoeducation, support therapy or psychotherapy. They are offered the HOP program after the trial.
The HOP program involves peer facilitated sessions, in which different stigma and disclosure related topics are introduced to the group, relevant tasks are completed individually, followed by group or two-and-two discussions related to the following topics: week 1 = pros and cons with disclosure, week 2 = different ways of disclosing, week 3 = formulating individual decisions of disclosure, week 6 = evaluating disclosure or non-disclosure in practice.
Also known as: Coming Out Proud (COP)
Stigma Stress Scale (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009)
8 items, from 1 (strongly disagree) to 7 (strongly agree)
Time frame: Change from T0 to T1 and T2 (assessed at T0 = week 0; T1 =week 3; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
Disclosure Distress (Rüsch et al., 2014a)
1 item "In general, how distressed or worried are you in terms of secrecy or disclosure of your mental illness to others?", from 1 (not at all) to 7 (very much)
Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
Warwick and Edinburgh Wellbeing Scale (WEMWBS) (Tennant et al 2007)
14-items, from 1 (not at all) to 5 (all the time)
Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
Satisfaction with life (Lehman, 1988)
1 item from Lehmans Quality of Life Scale, from 1 (very dissatisfied) to 7 (very satisfied)
Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
The Questionnaire about the Process of Recovery - 15 (QPR-15) (Niel et al 2007)
15 items short version, from 0 (strongly disagree) to 4 (strongly agree)
Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
Internalised Stigma of Mental Illness Inventory (ISMI-10) (Boyd, Otilingam, & Deforge, 2014)
10-item short version, from 1 (strongly disagree ) to 4 (strongly agree )
Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
Patient Health Questionnaire-4 (PHQ-9) (Kroenke et al 2009)
9 items, 0 (not at all) to 3 (nearly every day)
Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
Generalized Anxiety disorder (GAD-7) (Spitzer et al, 2006)
7 items, from 0 (not at all) to 3 (nearly every day)
Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
Disclosure
"Have you disclosed your mental illness the last three (or six) weeks?", YES/NO "How satisfied are you with that?", from 1 (very dissatisfied) to 7 (very satisfied)
Time frame: Assessed at T1 and T2 (T1= week 3 and T2 = week 6) This question was also included at T3 (last six weeks)
Feasibility of HOP program
Recruitment rates (numbers of participants in number of weeks) and drop-out rates.
Time frame: Tracked during trial and evaluated after completion (T2 = week 6)
Acceptability of HOP program participants
Semi-structured focus-group interview about acceptability with HOP program participants
Time frame: Assessed after T2 = week 6
Acceptability of HOP peer facilitators
Semi-structured focus-group interview about acceptability with HOP peer facilitators
Time frame: Assessed after T2 = week 6
Plan to share: No — The study protocol can be shared, but not the the actual data.
Ran from Apr 2024 to primary completion in Oct 2026, 30 months.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's 30 months is below that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Dec 2024 → Oct 2026 and completion Dec 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.